Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States

Emerging Infectious Diseases

Volumn 17, Issue 9, 2011, Pages 1591-1598

  Atkins, Charisma Y ^a   Patel, Anita ^a   Taylor Jr , Thomas H ^a   Biggerstaff, Matthew ^a   Merlin, Toby L ^a   Dulin, Stephanie M ^a   Erickson, Benjamin A ^a   Borse, Rebekah H ^a   Hunkler, Robert ^b   Meltzer, Martin I ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; DRUG USE; EPIDEMIC; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRESCRIPTION; PUBLIC HEALTH; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; HOSPITALIZATION; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MIDDLE AGED; OSELTAMIVIR; PANDEMICS; PRESCRIPTION DRUGS; UNITED STATES; YOUNG ADULT;

EID: 80052143124     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1709.110295     Document Type: Article

References (26)

1. Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, et al. Estimating the burden of 2009 pandemic infl uenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis. 2011;52 (Suppl 1):S75-82.
2. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season [cited 2010 Dec 18]. http://www.cdc.gov/H1N1flu/recommendations.htm#d
3. Health IMS. Data Assets, IMS Prescription Data [cited 2010 Dec 18]. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=a4284c30aaaa0210VgnVCM100000ed152ca2RCRD&vgnextchannel=bc42650204850210VgnVCM100000ed152ca2RCRD&vgnextfmt=default
4. Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan D, et al. Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009. Emerg Infect Dis. 2009;15:2004-7. doi:10.3201/eid1512.091413
5. Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. Euro Surveill 2010;15:pii:19565.
6. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by infl uenza A(H1N1)v, May 2009-an internetbased cross-sectional survey. Euro Surveill. 2009;14:pii:19287.
7. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on infl uenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-72. doi:10.1001/archinte.163.14.1667
8. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of infl uenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin. 2007;23:2961-70. doi:10.1185/030079907X242520
9. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and infl uenzarelated complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother. 2008;9:151-161. doi:10.1517/14656566.9.2.151
10. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther. 2007;29:2246-55. doi:10.1016/j. clinthera.2007.10.001
11. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med. 2008;10:131.
12. Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of infl uenza: a randomized, double-blind, placebo-controlled European study. J Infect. 2000;40:42-8. doi:10.1053/jinf.1999.0602
13. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother. 1991;35:1741-7.
14. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of effi cacy and safety of inhaled zanamivir in treatment of infl uenza A and B virus infections. Lancet. 1998;352:1877-81.
15. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, Sawy AE, Wat C, et al. Early administration of oral oseltamivir increases the benefi ts of influenza treatment. J Antimicrob Chemother. 2003;51:123-9. doi:10.1093/jac/dkg007
16. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of infl uenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874-80. doi:10.1056/NEJM199709253371302
17. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. 2001;161:212-7. doi:10.1001/archinte.161.2.212
18. Monto AS, Moult AB, Sharp SJ. Effect of zanamivir on duration and resolution of infl uenza symptoms. Clin Ther. 2000;22:1294-305. doi:10.1016/S0149-2918(00)83026-X
19. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Effi cacy and safety of oseltamivir in treatment of acute infl uenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-50. doi:10.1016/S0140-6736(00)02288-1
20. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Effi cacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute infl uenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-24. doi:10.1001/jama.283.8.1016
21. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of infl uenza in children. Pediatr Infect Dis J. 2001;20:127-33. doi:10.1097/00006454-200102000- 00002
22. Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, et al. Effects of adverse events of the projected population benefi ts and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med. 2011;165:112-8. doi:10.1001/archpediatrics.2010.182
23. Beigi RH, Wiringa AE, Bailey RR, Assi T-M, Lee BY. Economic value of seasonal and pandemic infl uenza during pregnancy. Clin Infect Dis. 2009;49:1784-92. doi:10.1086/649013
24. Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari N-A, et al. High costs of infl eunza: direct medical costs of infl uenza disease in young children. Vaccine. 2010;28:4913-9. doi:10.1016/j.vaccine.2010.05.036
25. Keren R, Zaoutis TE, Saddlemire S, Luan XQ, Coffin SE. Direct medical costs of infl uenza-related hospitalizations in children. Pediatrics. 2007;119:227.
26. Cox FM, Cobb MM, Chua WQ, McLaughlin TP, Okamoto LJ. Cost of treating infl uenza in emergency department and hospital settings. Am J Manage Care. 2000;6:205-14.